ARCT

#3092
Arcturus Therapeutics Holdings Inc. - Common Stock
7.9 3 USD
+0.13%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
7.87
7.96
년간 변동
5.86
24.14
일일 변동
+0.13%
월간 변동
-5.26%
6달 변화
+17.83%
년간 변동율
-37.21%
이전 종가
7.9 2
Open
7.9 0
저가
7.8 7
High
7.9 6
양
169
전체 차트 열기 Full chart

Financials

개요 성명 통계
4분기 연간
  • Market Capitalization 225.39 M
  • Employee 111
  • Founded 2013
  • CEO Joseph E. Payne
  • Website www.arcturusrx.com
  • Headquarter Delaware, United States
  • FIGI BBG00NNW8JK1
  • Industry 생명공학
총매출
순이익
주당 순이익(기본 EPS)
총부채
잉여 현금 흐름
현금 및 현금성 자산
주가수익비율
-2.55
주가매출액비율
2.05

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA. The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025.

뉴스